Comprehensive Stock Comparison
Compare Harmony Biosciences Holdings, Inc. (HRMY) vs BridgeBio Pharma, Inc. (BBIO) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | BBIO | 126.3% revenue growth vs HRMY's 21.5% |
| Quality / Margins | HRMY | 18.3% net margin vs BBIO's -145.3% |
| Stability / Safety | HRMY | Beta 0.55 vs BBIO's 1.04 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | BBIO | +90.5% vs HRMY's -15.7% |
| Efficiency (ROA) | HRMY | 12.5% ROA vs BBIO's -77.9% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Harmony Biosciences is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for rare neurological disorders. It generates nearly all its revenue from WAKIX — its medication for excessive daytime sleepiness in adult narcolepsy patients — with minimal contributions from other sources. The company's moat comes from its specialized expertise in rare neurological conditions and WAKIX's unique mechanism of action as a first-in-class treatment.
BridgeBio Pharma is a biopharmaceutical company focused on discovering and developing precision medicines for genetic diseases. It generates revenue primarily through drug development partnerships and potential future product sales — though currently in pre-revenue stage with multiple programs in clinical trials. The company's key advantage is its efficient hub-and-spoke operating model that allows rapid development of targeted therapies for rare genetic conditions.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
HRMY leads in 1 of 6 categories (Profitability & Efficiency). BBIO leads in 1 (Total Returns). 3 tied.
Financial Metrics (TTM)
HRMY is the larger business by revenue, generating $868M annually — 1.7x BBIO's $502M. HRMY is the more profitable business, keeping 18.3% of every revenue dollar as net income compared to BBIO's -145.3%. On growth, BBIO holds the edge at +25.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | HRMYHarmony Bioscienc… | BBIOBridgeBio Pharma,… |
|---|---|---|
| RevenueTrailing 12 months | $868M | $502M |
| EBITDAEarnings before interest/tax | $232M | -$560M |
| Net IncomeAfter-tax profit | $159M | -$729M |
| Free Cash FlowCash after capex | $0 | -$458M |
| Gross MarginGross profit ÷ Revenue | +77.2% | +94.4% |
| Operating MarginEBIT ÷ Revenue | +24.0% | -113.3% |
| Net MarginNet income ÷ Revenue | +18.3% | -145.3% |
| FCF MarginFCF ÷ Revenue | +40.1% | -91.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | +21.1% | +25.2% |
| EPS Growth (YoY)Latest quarter vs prior year | -55.3% | +28.6% |
Valuation Metrics
| Metric | HRMYHarmony Bioscienc… | BBIOBridgeBio Pharma,… |
|---|---|---|
| Market CapShares × price | $1.6B | $12.9B |
| Enterprise ValueMkt cap + debt − cash | $915M | $12.4B |
| Trailing P/EPrice ÷ TTM EPS | 10.53x | -17.54x |
| Forward P/EPrice ÷ next-FY EPS est. | 8.04x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 3.94x | — |
| Price / SalesMarket cap ÷ Revenue | 1.90x | 25.79x |
| Price / BookPrice ÷ Book value/share | 1.92x | — |
| Price / FCFMarket cap ÷ FCF | 4.74x | — |
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), HRMY scores 5/9 vs BBIO's 3/9, reflecting solid financial health.
| Metric | HRMYHarmony Bioscienc… | BBIOBridgeBio Pharma,… |
|---|---|---|
| ROE (TTM)Return on equity | +18.2% | — |
| ROA (TTM)Return on assets | +12.5% | -77.9% |
| ROICReturn on invested capital | +59.5% | — |
| ROCEReturn on capital employed | +22.6% | -80.6% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 3 |
| Debt / EquityFinancial leverage | 0.02x | — |
| Net DebtTotal debt minus cash | -$733M | -$560M |
| Cash & Equiv.Liquid assets | $753M | $570M |
| Total DebtShort + long-term debt | $20M | $10M |
| Interest CoverageEBIT ÷ Interest expense | 15.43x | -6.10x |
Total Returns (with DRIP)
A $10,000 investment in BBIO five years ago would be worth $9,245 today (with dividends reinvested), compared to $7,877 for HRMY. Over the past 12 months, BBIO leads with a +90.5% total return vs HRMY's -15.7%. The 3-year compound annual growth rate (CAGR) favors BBIO at 79.9% vs HRMY's -13.5% — a key indicator of consistent wealth creation.
| Metric | HRMYHarmony Bioscienc… | BBIOBridgeBio Pharma,… |
|---|---|---|
| YTD ReturnYear-to-date | -23.6% | -15.0% |
| 1-Year ReturnPast 12 months | -15.7% | +90.5% |
| 3-Year ReturnCumulative with dividends | -35.2% | +482.1% |
| 5-Year ReturnCumulative with dividends | -21.2% | -7.6% |
| 10-Year ReturnCumulative with dividends | -22.9% | +141.3% |
| CAGR (3Y)Annualised 3-year return | -13.5% | +79.9% |
Risk & Volatility
HRMY is the less volatile stock with a 0.55 beta — it tends to amplify market swings less than BBIO's 1.04 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. BBIO currently trades 78.3% from its 52-week high vs HRMY's 69.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | HRMYHarmony Bioscienc… | BBIOBridgeBio Pharma,… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.55x | 1.04x |
| 52-Week HighHighest price in past year | $40.87 | $84.94 |
| 52-Week LowLowest price in past year | $25.52 | $28.33 |
| % of 52W HighCurrent price vs 52-week peak | +69.8% | +78.3% |
| RSI (14)Momentum oscillator 0–100 | 31.6 | 39.0 |
| Avg Volume (50D)Average daily shares traded | 517K | 2.5M |
Analyst Outlook
Wall Street rates HRMY as "Buy" and BBIO as "Buy". Consensus price targets imply 68.8% upside for HRMY (target: $48) vs 48.8% for BBIO (target: $99).
| Metric | HRMYHarmony Bioscienc… | BBIOBridgeBio Pharma,… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $48.17 | $98.92 |
| # AnalystsCovering analysts | 13 | 26 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.4% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Aug 20 | Feb 26 | Change |
|---|---|---|---|
| Harmony Biosciences… (HRMY) | 100 | 102.24 | +2.2% |
| BridgeBio Pharma, I… (BBIO) | 100 | 283.27 | +183.3% |
BridgeBio Pharma, I… (BBIO) returned -8% over 5 years vs Harmony Biosciences… (HRMY)'s -21%.
Chart 2Revenue Growth — 10 Years
| Stock | 2017 | 2025 | Change |
|---|---|---|---|
| Harmony Biosciences… (HRMY) | $0.00 | $868M | — |
| BridgeBio Pharma, I… (BBIO) | $0.00 | $502M | — |
BridgeBio Pharma, Inc.'s revenue grew from $0M (2017) to $502M (2025) — a 0.0% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2019 | 2025 | Change |
|---|---|---|---|
| Harmony Biosciences… (HRMY) | -25.4% | 18.3% | +172.1% |
| BridgeBio Pharma, I… (BBIO) | -6.4% | -145.3% | -2162.2% |
Harmony Biosciences Holdings, Inc.'s net margin went from -25% (2019) to 18% (2025). BridgeBio Pharma, Inc.'s net margin went from -6% (2019) to -145% (2025).
Chart 4P/E Ratio History — 5 Years
| Stock | 2021 | 2025 | Change |
|---|---|---|---|
| Harmony Biosciences… (HRMY) | 73.5 | 13.8 | -81.2% |
Harmony Biosciences Holdings, Inc. has traded in a 14x–74x P/E range over 5 years; current trailing P/E is ~11x.
Chart 5EPS Growth — 10 Years
| Stock | 2017 | 2025 | Change |
|---|---|---|---|
| Harmony Biosciences… (HRMY) | -1.42 | 2.71 | +290.8% |
| BridgeBio Pharma, I… (BBIO) | -0.33 | -3.79 | -1048.5% |
BridgeBio Pharma, Inc.'s EPS grew from $-0.33 (2017) to $-3.79 (2025).
Chart 6Free Cash Flow — 5 Years
Harmony Biosciences Holdings, Inc. generated $348M FCF in 2025 (+254% vs 2021). BridgeBio Pharma, Inc. generated $-447M FCF in 2025 (+18% vs 2021).
HRMY vs BBIO: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is HRMY or BBIO a better buy right now?
Harmony Biosciences Holdings, Inc. (HRMY) offers the better valuation at 10.5x trailing P/E (8.0x forward), making it the more compelling value choice. Analysts rate Harmony Biosciences Holdings, Inc. (HRMY) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — HRMY or BBIO?
Over the past 5 years, BridgeBio Pharma, Inc. (BBIO) delivered a total return of -7.6%, compared to -21.2% for Harmony Biosciences Holdings, Inc. (HRMY). A $10,000 investment in BBIO five years ago would be worth approximately $9K today (assuming dividends reinvested). Over 10 years, the gap is even starker: BBIO returned +141.3% versus HRMY's -22.9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — HRMY or BBIO?
By beta (market sensitivity over 5 years), Harmony Biosciences Holdings, Inc. (HRMY) is the lower-risk stock at 0.55β versus BridgeBio Pharma, Inc.'s 1.04β — meaning BBIO is approximately 87% more volatile than HRMY relative to the S&P 500.
04Which has better profit margins — HRMY or BBIO?
Harmony Biosciences Holdings, Inc. (HRMY) is the more profitable company, earning 18.3% net margin versus -145.3% for BridgeBio Pharma, Inc. — meaning it keeps 18.3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HRMY leads at 24.0% versus -113.3% for BBIO. At the gross margin level — before operating expenses — BBIO leads at 94.4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Is HRMY or BBIO more undervalued right now?
Analyst consensus price targets imply the most upside for HRMY: 68.8% to $48.17.
06Which pays a better dividend — HRMY or BBIO?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is HRMY or BBIO better for a retirement portfolio?
For long-horizon retirement investors, Harmony Biosciences Holdings, Inc. (HRMY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.55)). Both have compounded well over 10 years (HRMY: -22.9%, BBIO: +141.3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between HRMY and BBIO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: HRMY is a small-cap deep-value stock; BBIO is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.